Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma
- PMID: 25564571
- DOI: 10.1158/1078-0432.CCR-13-3316
Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma
Abstract
Purpose: The development of a genetic signature for the identification of high-risk cutaneous melanoma tumors would provide a valuable prognostic tool with value for stage I and II patients who represent a remarkably heterogeneous group with a 3% to 55% chance of disease progression and death 5 years from diagnosis.
Experimental design: A prognostic 28-gene signature was identified by analysis of microarray expression data. Primary cutaneous melanoma tumor tissue was evaluated by RT-PCR for expression of the signature, and radial basis machine (RBM) modeling was performed to predict risk of metastasis.
Results: RBM analysis of cutaneous melanoma tumor gene expression reports low risk (class 1) or high risk (class 2) of metastasis. Metastatic risk was predicted with high accuracy in development (ROC = 0.93) and validation (ROC = 0.91) cohorts of primary cutaneous melanoma tumor tissue. Kaplan-Meier analysis indicated that the 5-year disease-free survival (DFS) rates in the development set were 100% and 38% for predicted classes 1 and 2 cases, respectively (P < 0.0001). DFS rates for the validation set were 97% and 31% for predicted classes 1 and 2 cases, respectively (P < 0.0001). Gene expression profile (GEP), American Joint Committee on Cancer stage, Breslow thickness, ulceration, and age were independent predictors of metastatic risk according to Cox regression analysis.
Conclusions: The GEP signature accurately predicts metastasis risk in a multicenter cohort of primary cutaneous melanoma tumors. Preliminary Cox regression analysis indicates that the signature is an independent predictor of metastasis risk in the cohort presented.
©2015 American Association for Cancer Research.
Similar articles
-
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.BMC Cancer. 2018 Feb 5;18(1):130. doi: 10.1186/s12885-018-4016-3. BMC Cancer. 2018. PMID: 29402264 Free PMC article.
-
A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.Clin Cancer Res. 2015 Nov 1;21(21):4903-12. doi: 10.1158/1078-0432.CCR-14-2566. Epub 2015 Jun 18. Clin Cancer Res. 2015. PMID: 26089374 Free PMC article.
-
Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.J Am Acad Dermatol. 2017 May;76(5):818-825.e3. doi: 10.1016/j.jaad.2016.11.051. Epub 2017 Jan 19. J Am Acad Dermatol. 2017. PMID: 28110997
-
Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma.Am J Clin Dermatol. 2019 Dec;20(6):763-770. doi: 10.1007/s40257-019-00464-4. Am J Clin Dermatol. 2019. PMID: 31359351 Free PMC article. Review.
-
Gene expression profiling of primary cutaneous melanoma.Verh K Acad Geneeskd Belg. 2007;69(1):23-45. Verh K Acad Geneeskd Belg. 2007. PMID: 17427873 Review.
Cited by
-
β3 integrin immunohistochemistry as a method to predict sentinel lymph node status in patients with primary cutaneous melanoma.Int J Dermatol. 2020 Oct;59(10):1241-1248. doi: 10.1111/ijd.15125. Epub 2020 Aug 9. Int J Dermatol. 2020. PMID: 32772371 Free PMC article.
-
The Use of Gene Expression Profiling and Biomarkers in Melanoma Diagnosis and Predicting Recurrence: Implications for Surveillance and Treatment.Cancers (Basel). 2024 Jan 30;16(3):583. doi: 10.3390/cancers16030583. Cancers (Basel). 2024. PMID: 38339333 Free PMC article. Review.
-
Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.Cancers (Basel). 2022 Jun 9;14(12):2854. doi: 10.3390/cancers14122854. Cancers (Basel). 2022. PMID: 35740520 Free PMC article.
-
Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential.J Am Coll Surg. 2019 May;228(5):721-729. doi: 10.1016/j.jamcollsurg.2019.02.040. Epub 2019 Feb 19. J Am Coll Surg. 2019. PMID: 30794864 Free PMC article.
-
Robust dimethyl-based multiplex-DIA doubles single-cell proteome depth via a reference channel.Mol Syst Biol. 2023 Sep 12;19(9):e11503. doi: 10.15252/msb.202211503. Epub 2023 Aug 21. Mol Syst Biol. 2023. PMID: 37602975 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical